PRA Health Sciences Inc (PRAH) Shares Bought by Sheets Smith Wealth Management

Sheets Smith Wealth Management grew its stake in PRA Health Sciences Inc (NASDAQ:PRAH) by 30.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,304 shares of the medical research company’s stock after purchasing an additional 1,914 shares during the quarter. Sheets Smith Wealth Management’s holdings in PRA Health Sciences were worth $756,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of PRAH. Capital Research Global Investors raised its position in shares of PRA Health Sciences by 318.3% in the second quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock valued at $163,172,000 after purchasing an additional 1,655,336 shares during the period. BlackRock Inc. raised its position in shares of PRA Health Sciences by 28.2% in the second quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock valued at $274,759,000 after purchasing an additional 805,573 shares during the period. Wells Fargo & Company MN raised its position in shares of PRA Health Sciences by 55.8% in the third quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock valued at $91,943,000 after purchasing an additional 432,449 shares during the period. Hood River Capital Management LLC raised its position in shares of PRA Health Sciences by 80.3% in the second quarter. Hood River Capital Management LLC now owns 619,924 shares of the medical research company’s stock valued at $46,500,000 after purchasing an additional 276,045 shares during the period. Finally, Stephens Investment Management Group LLC raised its position in shares of PRA Health Sciences by 236.9% in the third quarter. Stephens Investment Management Group LLC now owns 391,672 shares of the medical research company’s stock valued at $29,834,000 after purchasing an additional 275,414 shares during the period. 98.22% of the stock is currently owned by institutional investors.

PRA Health Sciences Inc (NASDAQ:PRAH) opened at $90.06 on Friday. PRA Health Sciences Inc has a 1 year low of $54.08 and a 1 year high of $92.84. The company has a market cap of $5,788.19, a PE ratio of 50.31, a P/E/G ratio of 1.28 and a beta of 0.41. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, beating the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The firm had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. During the same period last year, the firm earned $0.64 EPS. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. analysts anticipate that PRA Health Sciences Inc will post 3.2 EPS for the current year.

In other PRA Health Sciences news, insider David W. Dockhorn sold 72,850 shares of the firm’s stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $90.83, for a total value of $6,616,965.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Matthew P. Young sold 5,115 shares of the firm’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 150,815 shares of company stock worth $13,642,620. Insiders own 2.10% of the company’s stock.

A number of research firms recently commented on PRAH. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $103.00 price target on the stock in a research report on Thursday. Mizuho began coverage on shares of PRA Health Sciences in a research report on Thursday, September 21st. They set a “buy” rating and a $82.00 price target on the stock. BidaskClub lowered shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 5th. Robert W. Baird reaffirmed a “buy” rating and set a $88.00 price target on shares of PRA Health Sciences in a research report on Monday, October 9th. Finally, KeyCorp reaffirmed a “buy” rating and set a $93.00 price target (up from $86.00) on shares of PRA Health Sciences in a research report on Monday, October 30th. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. PRA Health Sciences currently has an average rating of “Buy” and a consensus price target of $92.00.

ILLEGAL ACTIVITY NOTICE: This report was posted by Stock Observer and is the property of of Stock Observer. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.thestockobserver.com/2018/01/13/pra-health-sciences-inc-prah-shares-bought-by-sheets-smith-wealth-management.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply